Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
Oppenheimer: Buy Five Prime Therapeutics, It's Worth $45/Share
7 Trends Drug Investors Should Know
Moody's dings Glaxo's credit rating outlook citing intense competition in U.S. and impact of restructuring activities (Seeking Alpha)
Related THRX
Morning Market Losers
18 Biotech Stocks These Wall Street Analysts Are Tracking

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...